J Pediatr Intensive Care 2020; 09(01): 021-026
DOI: 10.1055/s-0039-1695061
Original Article
Georg Thieme Verlag KG Stuttgart · New York

Invasive Candida Infections in a Pediatric Intensive Care Unit in Turkey: Evaluation of an 11-Year Period

Nagehan Aslan
1   Department of Pediatric Intensive Care, Cukurova University Faculty of Medicine, Adana, Turkey
,
Dincer Yildizdas
1   Department of Pediatric Intensive Care, Cukurova University Faculty of Medicine, Adana, Turkey
,
Derya Alabaz
2   Department of Pediatric Infectious Disease, Cukurova University Faculty of Medicine, Adana, Turkey
,
Ozden Ozgur Horoz
1   Department of Pediatric Intensive Care, Cukurova University Faculty of Medicine, Adana, Turkey
,
Ahmet Yontem
1   Department of Pediatric Intensive Care, Cukurova University Faculty of Medicine, Adana, Turkey
,
Emine Kocabas
2   Department of Pediatric Infectious Disease, Cukurova University Faculty of Medicine, Adana, Turkey
› Author Affiliations
Further Information

Publication History

19 May 2019

13 July 2019

Publication Date:
06 September 2019 (online)

Abstract

The aim of this study was to evaluate the Candida species, predisposing factors, antifungal treatment approaches, and clinical outcomes of invasive Candida infections (ICIs) in a tertiary pediatric intensive care unit (PICU). A retrospective study was performed from January 2008 to January 2019 including 102 children with ICIs who were admitted to a university hospital in southeastern Turkey. Positive blood cultures were detected in 43 (42.1%) patients, and positive urine cultures were detected in 59 (57.8%). According to our results, Candida albicans (42.2%) was the most common species for all isolates followed by C. parapsilosis (17.6%). In our patient population, non-albicans Candida species were dominant (57.8%) in all isolates. The most common facilitating factor in our study was the use of mechanical ventilator support (87.3%). The mortality rate of our patients with ICIs was 13.7%. Candida albicans was found to have the highest mortality rate among all Candida species (30.7%). When we compared patients with C. albicans and those with non-albicans Candida species in terms of risk factors, we detected a significant difference between the two groups for total parenteral nutrition use (p = 0.027). Fluconazole was the most preferred (58.8%) treatment option in our PICU for ICIs. Our results showed an increased trend in micafungin use in recent years. ICIs are a significant problem due to the high mortality and morbidity rates in critically ill pediatric patients in PICUs. In recent years, an increase in Candida infections caused by non-albicans Candida species has been reported. Multicenter prospective studies are needed to determine the risk factors for ICIs.

 
  • References

  • 1 Pappas PG, Kauffman CA, Andes D. , et al; Infectious Diseases Society of America. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48 (05) 503-535
  • 2 Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007; 20 (01) 133-163
  • 3 Zaoutis T. Candidemia in children. Curr Med Res Opin 2010; 26 (07) 1761-1768
  • 4 Mesini A, Bandettini R, Caviglia I. , et al. Candida infections in paediatrics: results from a prospective single-centre study in a tertiary care children's hospital. Mycoses 2017; 60 (02) 118-123
  • 5 Delaloye J, Calandra T. Invasive candidiasis as a cause of sepsis in the critically ill patient. Virulence 2014; 5 (01) 161-169
  • 6 Orasch C, Mertz D, Garbino J. , et al; Fungal Infection Network of Switzerland (FUNGINOS). Fluconazole non-susceptible breakthrough candidemia after prolonged low-dose prophylaxis: a prospective FUNGINOS study. J Infect 2018; 76 (05) 489-495
  • 7 Harrington R, Kindermann SL, Hou Q, Taylor RJ, Azie N, Horn DL. Candidemia and invasive candidiasis among hospitalized neonates and pediatric patients. Curr Med Res Opin 2017; 33 (10) 1803-1812
  • 8 Montagna MT, Lovero G, Borghi E. , et al. Candidemia in intensive care unit: a nationwide prospective observational survey (GISIA-3 study) and review of the European literature from 2000 through 2013. Eur Rev Med Pharmacol Sci 2014; 18 (05) 661-674
  • 9 Tragiannidis A, Fegeler W, Rellensmann G. , et al. Candidaemia in a European paediatric university hospital: a 10-year observational study. Clin Microbiol Infect 2012; 18 (02) E27-E30
  • 10 Guery BP, Arendrup MC, Auzinger G. , et al. Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: part I. Epidemiology and diagnosis. Intensive Care Med 2009; 35 (01) 55-62
  • 11 Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008; 36 (05) 309-332
  • 12 Pfaller MA, Messer SA, Hollis RJ. , et al. Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location in the United States in 2001 to 2007. J Clin Microbiol 2009; 47 (10) 3185-3190
  • 13 Pfaller MA, Diekema DJ. Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus . J Clin Microbiol 2004; 42 (10) 4419-4431
  • 14 Watson RS, Carcillo JA, Linde-Zwirble WT, Clermont G, Lidicker J, Angus DC. The epidemiology of severe sepsis in children in the United States. Am J Respir Crit Care Med 2003; 167 (05) 695-701
  • 15 Pagano L, Caira M, Candoni A. , et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 2006; 91 (08) 1068-1075
  • 16 Profumo RJ. Pediatric liver transplant recipients: mortality analysis over 20 years. J Insur Med 2006; 38 (01) 3-8
  • 17 Almooosa Z, Ahmed GY, Omran A. , et al. Invasive candidiasis in pediatric patients at King Fahad Medical City in Central Saudi Arabia. A 5-year retrospective study. Saudi Med J 2017; 38 (11) 1118-1124
  • 18 Palazzi DL, Arrieta A, Castagnola E. , et al. Candida speciation, antifungal treatment and adverse events in pediatric invasive candidiasis: results from 441 infections in a prospective, multi-national study. Pediatr Infect Dis J 2014; 33 (12) 1294-1296
  • 19 Dutta A, Palazzi DL. Candida non-albicans versus Candida albicans fungemia in the non-neonatal pediatric population. Pediatr Infect Dis J 2011; 30 (08) 664-668
  • 20 Omrani AS, Makkawy EA, Baig K. , et al. Ten-year review of invasive Candida infections in a tertiary care center in Saudi Arabia. Saudi Med J 2014; 35 (08) 821-826
  • 21 Sütçü M, Acar M, Genç GE. , et al. Evaluation of Candida species and antifungal susceptibilities among children with invasive candidiasis. Turk Pediatri Ars 2017; 52 (03) 145-153
  • 22 Noni M, Stathi A, Vaki I, Velegraki A, Zachariadou L, Michos A. Changing epidemiology of invasive candidiasis in children during a 10-year period. J Fungi (Basel) 2019; 5 (01) 19
  • 23 Celebi S, Hacimustafaoglu M, Ozdemir O, Ozkaya G. Nosocomial candidaemia in children: results of a 9-year study. Mycoses 2008; 51 (03) 248-257
  • 24 Devrim İ, Demirağ B, Yaman Y. , et al. A 7-year study of the distribution of nosocomial candidemia in children with cancer. Turk J Pediatr 2015; 57 (03) 225-229
  • 25 Öncü B, Belet N, Emecen AN, Birinci A. Health care-associated invasive Candida infections in children. Med Mycol 2019 (e-pub ahead of print). doi: 10.1093/mmy/myz005
  • 26 Sievert DM, Ricks P, Edwards JR. , et al; National Healthcare Safety Network (NHSN) Team and Participating NHSN Facilities. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol 2013; 34 (01) 1-14
  • 27 Benjamin Jr DK, Stoll BJ, Gantz MG. , et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Neonatal candidiasis: epidemiology, risk factors, and clinical judgment. Pediatrics 2010; 126 (04) e865-e873
  • 28 Acar A, Oncül O, Küçükardali Y, Ozyurt M, Haznedaroğlu T, Cavuşlu S. Yoğun bakim ünitelerinde saptanan Candida enfeksiyonlarinin epidemiyolojik özellikleri ve mortaliteye etki eden risk faktörleri. Mikrobiyol Bul 2008; 42 (03) 451-461
  • 29 Çekin Y, Pekintürk N, Çekin AH. Evaluation of species distribution and antifungal resistance of Candida isolates from hospitalized patients. J Clin Anal Med 2015; 6: 8-11
  • 30 Hazırolan G, Yıldıran D, Baran I, Mumcuoğlu İ, Aksu N. Yatan hasta örneklerinden izole edilen Candida izolatlarının tür dağılımlarının ve antifungal duyarlılık profillerinin değerlendirilmesi. Turk Hij Deney Biyol Derg 2015; 72: 17-26
  • 31 Stamos JK, Rowley AH. Candidemia in a pediatric population. Clin Infect Dis 1995; 20 (03) 571-575
  • 32 Filioti J, Spiroglou K, Roilides E. Invasive candidiasis in pediatric intensive care patients: epidemiology, risk factors, management, and outcome. Intensive Care Med 2007; 33 (07) 1272-1283
  • 33 Conde-Rosa A, Amador R, Pérez-Torres D. , et al. Candidemia distribution, associated risk factors, and attributed mortality at a university-based medical center. P R Health Sci J 2010; 29 (01) 26-29
  • 34 Blyth CC, Chen SC, Slavin MA. , et al; Australian Candidemia Study. Not just little adults: candidemia epidemiology, molecular characterization, and antifungal susceptibility in neonatal and pediatric patients. Pediatrics 2009; 123 (05) 1360-1368
  • 35 Pappas PG, Kauffman CA, Andes DR. , et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 62: 1-50
  • 36 Hope WW, Castagnola E, Groll AH. , et al; ESCMID Fungal Infection Study Group. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp. Clin Microbiol Infect 2012; 18 (Suppl. 07) 38-52